WHOOP product image

Courtesy of Company

The consumer wellness wearable device worn by fitness enthusiasts was designed to optimize sleep and track workouts, but the company is using its latest round of funding to go mainstream and become the control center for personal healthcare.

WHOOP closed a $575 million Series G raise led by Collaborative Fund at a $10.1 billion valuation in March 2026. Celebrity-athlete investors like Lebron James and Cristiano Ronaldo topped the headlines, but perhaps the more meaningful cap table additions were two strategic investors — Abbott, the global medical device and diagnostics powerhouse behind products ranging from continuous glucose monitors to cardiovascular devices, and Mayo Clinic, the academic medical center and clinical research institution widely regarded as one of the most influential health systems in the world. Two healthcare institutions putting institutional weight behind a company that built its brand on recovery scores for athletes is a vote of confidence for the new health-focused mandate that CEO Will Ahmed is embracing. “Healthcare systems around the world are reactive…We are building the personal health platform that people use to improve their health and livelihood.”

WHOOP Creeps Closer to the Medical Line

Originally marketed to the fitness consumer, WHOOP has steadily expanded into a broader health platform strategy. The company’s core product remains a screenless wearable that continuously monitors physiological signals including heart rate, heart rate variability, respiratory rate, sleep performance, skin temperature, and activity strain. But over the last two years, WHOOP has layered increasingly clinical capabilities on top of that consumer wellness foundation through tiered subscription offerings that now extend into diagnostics, cardiovascular monitoring, and personalized health guidance.

The shift is visible in the company’s membership structure itself. Higher-tier plans now bundle features that begin to resemble services traditionally associated with healthcare providers and remote patient monitoring platforms rather than fitness apps. WHOOP Life priced at $359.00 per year, for example, incorporates an FDA-cleared electrocardiogram (ECG) sensor software, which enables users to take on-demand ECG spot checks to monitor for atrial fibrillation (AFib) and check for irregular heart rhythms directly from the wrist. In addition, WHOOP Advanced Labs mirrors platforms like Function and Superpower, in giving users access to extensive blood biomarker tests spanning metabolic, hormonal, cardiovascular, and longevity-related markers. The company has also recently introduced clinician-on-demand access and AI-driven health insights designed to help users interpret increasingly complex health data. Taken together, the evolution reflects a deliberate strategy: transform WHOOP from a workout optimization device into a vertically integrated personal health operating system sitting somewhere between consumer wellness brand, digital health platform, and regulated medical device company.

FDA Slaps WHOOP on the Wrist

That strategy, however, is beginning to test the boundaries of where consumer wellness ends and regulated healthcare begins. In May 2025, WHOOP launched a blood pressure insights feature that estimated systolic and diastolic readings using signals such as heart rate variability (HRV), blood flow dynamics, and optical sensor data collected through the wearable. Unlike its ECG functionality, which received FDA 510(k) clearance as a Class II over-the-counter electrocardiograph software device, the blood pressure feature entered the market without formal FDA clearance. WHOOP positioned the tool as a generalized wellness feature intended to provide directional insights rather than clinical-grade diagnostics.

The FDA disagreed. In July 2025, the agency issued a warning letter arguing that blood pressure monitoring is inherently tied to disease detection and hypertension management, placing the feature within medical device territory. WHOOP pushed back publicly and reportedly declined to remove the feature, arguing that the software falls within the wellness software exemptions created under the 21st Century Cures Act because it does not explicitly diagnose disease or direct treatment decisions. The standoff underscores the larger question hanging over the company’s healthcare ambitions: whether regulators will ultimately allow wellness platforms to gradually absorb functions historically reserved for medical devices and healthcare providers without being subjected to the same evidentiary and regulatory standards.

WHOOP Dips into the CMS Pool to Tackle Chronic Disease

But even as WHOOP faces increasing regulatory scrutiny from the FDA, the company is simultaneously gaining credibility from another powerful arm of the U.S. healthcare system. In 2026, WHOOP was selected to participate in the Centers for Medicare & Medicaid Services’ ACCESS model, a program designed to support technology-enabled chronic disease management and improve care for Medicare beneficiaries with conditions such as diabetes, hypertension, and cardiovascular disease. Household health tech names including Doctronic, the AI-powered personal doctor platform, Headspace, and Noom were also selected for the program. The initiative reflects CMS’s broader push toward remote monitoring, preventative care, and longitudinal patient engagement — areas where wearable devices are increasingly positioned as low-cost tools for continuous health tracking. The pilot program will run for 10 years beginning July 5, 2026.

The significance for WHOOP extends far beyond institutional validation. Penetrating the Medicare ecosystem opens access to an entirely different customer demographic than the company’s traditional base of athletes, executives, and wellness enthusiasts. Chronic disease management represents one of the largest and most expensive segments of the U.S. healthcare system, with Medicare spending heavily concentrated among patients with cardiovascular and metabolic conditions. Participation in CMS-backed programs creates a potential reimbursement and distribution pathway that could move WHOOP from discretionary consumer subscription into insurer-supported healthcare infrastructure.

Remote Patient Monitoring Is Big Business

WHOOP’s expansion into health is happening alongside a much larger shift underway across the healthcare system: the rapid rise of remote patient monitoring, or RPM. What was once considered a niche clinical tool has evolved into one of the fastest-growing segments in preventative healthcare as insurers, providers, employers, and federal health programs search for ways to manage chronic disease outside the hospital setting. The infrastructure for reimbursing continuous, device-generated health data is no longer theoretical — it already exists and is scaling rapidly. According to IMARC Group, the remote patient monitoring market reached roughly $1.5 billion in 2023 and is projected to grow to $4.7 billion by 2032. And wearable technologies, including smartwatches, fitness trackers, and biosensors, are at the vanguard of this change, delivering real-time health data and allowing for continuous patient monitoring outside of traditional clinical settings.

The economic drivers behind that growth are straightforward. Chronic disease accounts for roughly 90 percent of the nation’s $5.3 trillion annual healthcare expenditure, creating enormous pressure on payers and health systems to identify lower-cost models centered around prevention and earlier intervention. “Healthcare is shifting from episodic care to longitudinal monitoring,” said Dr. Elizabeth Ofili, cardiologist and health entrepreneur. “The ability to continuously collect physiologic data outside the clinic creates opportunities to identify deterioration earlier, personalize interventions, and potentially reduce downstream cardiovascular and metabolic complications. The future of medicine will increasingly rely on integrating patient-generated data into routine care delivery.”

One startup leading in this space is Cadence, a remote patient care (RPC) platform which has raised $141 million to date and supports 85,000 seniors across 22 health systems across the country, to extend senior care at home. Cadence provides in-home vital sign monitoring and personalized coaching and also leverages AI to review patient data generated from connected devices, effectively extending primary care at scale. The Series B startup recently announced strategic partnerships with Hartford Healthcare, Memorial Hermann, Corewell Health, Sharp Rees-Stealy Medical Group, Village Medical, and Yale New Haven Health, and was also selected for the same CMS ACCESS program as WHOOP.

What has historically limited the market, however, is not demand but execution. Early remote patient monitoring programs generated enormous amounts of patient data without clear clinical workflows for interpreting it, escalating it, or integrating it into already overburdened healthcare systems. Providers have long cited challenges including alert fatigue, reimbursement uncertainty, patient adherence drop-off, data accuracy concerns, and the operational burden of managing continuous streams of biometric information. Many RPM programs also relied on active patient compliance — requiring users to remember to manually take readings using blood pressure cuffs, pulse oximeters, or weight scales — creating friction that often undermined long-term engagement. As payers increasingly scrutinize the economics and clinical value of RPM programs, the industry is entering a new phase where the data must be consistent, accurate and capable of driving measurable health outcomes.

Consumer wearables fundamentally alter the equation. Devices like WHOOP, Apple Watch, and Oura Ring generate continuous passive streams of biometric data — HRV, sleep stages, respiratory rate, blood oxygen levels, movement, strain, and recovery metrics — often without requiring any conscious action from the user. That always-on longitudinal data stream is precisely what is making wellness wearables increasingly attractive to healthcare systems and chronic disease management programs.

The distinction may ultimately prove commercially significant. A peer-reviewed study analyzing nearly one million days and nights of longitudinal WHOOP subscriber data found evidence that sustained wearable engagement correlated with healthier habits and improved physiological outcomes over time - lower resting heart rate, higher HRV, longer and more consistent sleep, and greater weekly and daily physical activity duration. The wearable, in other words, functions not only as a monitoring tool but also as a behavioral reinforcement mechanism.

What’s Next for WHOOP’s Health Evolution?

The CMS ACCESS partnership raises a broader question for WHOOP: how does the company evolve if it fully commits to healthcare? Participation in a federal chronic disease initiative places the company on a trajectory far removed from its original positioning in the fitness and wellness vertical. Instead, it points toward a future where WHOOP functions as a continuous health monitoring and preventative care platform integrated into employer health plans, clinical workflows, and reimbursement systems.

That is where the strategic significance of investors like Abbott and the Mayo Clinic becomes clearer. Abbott brings decades of expertise navigating FDA regulation, diagnostics, cardiovascular monitoring, and reimbursement pathways through products like continuous glucose monitors and remote patient monitoring technologies. Mayo Clinic, meanwhile, brings clinical validation, research infrastructure, physician networks, and institutional credibility within healthcare systems. Together, the two organizations provide WHOOP with something most wellness startups lack: a potential bridge into regulated healthcare and enterprise medicine.

The roadmap already exists elsewhere in the market. Companies like Reperio Health are building infrastructure specifically around chronic disease prevention, employer healthcare spending, and payer reimbursement. Reperio partners with employers and health plans to distribute FDA-cleared at-home screening kits that measure blood pressure, cholesterol, glucose, triglycerides, and cardiovascular risk markers, while connecting users immediately to licensed clinicians through virtual care workflows. The business model is not built around affluent consumers paying out-of-pocket subscriptions, but around employers and insurers seeking lower-cost preventative care and earlier intervention for chronic disease populations. “Getting data to people and then saying ‘here you go, good luck’ is not helpful,” Reperio CEO Travis Rush shared. “Having a fully rounded solution — data, a way to interpret it, and next steps — is critical.”

WHOOP’s recent launch of clinician-on-demand services suggests the company understands the same dynamic. The wearable itself may ultimately become only the front-end data collection layer. The larger opportunity lies in what happens after the data is generated: interpretation, clinical guidance, risk stratification, preventative interventions, and ongoing care management. In other words, the company is no longer merely trying to optimize athletic performance — it is inching toward a far more ambitious goal: becoming an always-on early warning system for optimizing personalized health. CEO Will Ahmed has discussed that vision publicly. “I do envision the potential of WHOOP to predict that you’re going to have a heart attack before you do,” he told The New York Times.